An Animal Model Further Uncovers the Role of Mutant Braf during Papillary Thyroid Cancer Development

Koelsch, Bernd; Theurer, Sarah; Staniszewska, Magdalena; Heupel, Jacqueline; Koch, Amelie H. R.; Mergener, Svenja; Walk, Franziska; Fischer, Christine; Kutritz, Andrea; Schmid, Kurt Werner; Kindler‐Röhrborn, Andrea

doi:10.1016/j.ajpath.2019.11.006

Cited by 3 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, the results of the present study demonstrated that the LNM rate was significantly increased and was correlated with BRAF wild-type in PTMC, which indicated that the BRAF V600E mutation in PTMC was less aggressive; this result differs to that from a previous meta-analysis (22). A previous study revealed that the majority of PTMC cases with a BRAF V600E mutation do not express BRAF V600E protein (31).…”

Section: Univariate Analysis Multivariate Analysis ------------------contrasting

confidence: 85%

Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma

et al. 2021

View full text Add to dashboard Cite

With the increasing incidence of papillary thyroid cancer (PTC), it is important to risk-stratify patients who may have a more aggressive tumor biology. The present study aimed to evaluate the risk factors for lymph node metastasis (LNM) in patients with PTC, which may provide a significant reference for clinical diagnosis and treatment. In total, 1,045 patients with PTC [313 with PT microcarcinoma (PTMC) and 732 with non-PTMC] between August 2016 and August 2019 were investigated. The B-type Raf kinase (BRAF) V600E mutation was tested in all samples. The clinical data (sex, age, tumor location, sample type and pathological features) were retrospectively analyzed. Logistic regression analysis was performed to evaluate independent risk factors for LNM. A total of 181/313 (57.8%) PTMC cases and 145/732 (19.8%) non-PTMC cases had a BRAF V600E mutation. In the PTMC cases, significant differences in sex and sample type were identified (BRAF V600E mutation vs. wild-type). In the non-PTMC cases, significant differences in sex and age were identified (BRAF V600E mutation vs. wild-type). Female sex and tumor diameter ≤1 cm were significant independent predictors of LNM in PTC. In PTMC, female sex was a significant independent predictor of LNM. A bilateral tumor was an independent protective factor for LNM in PTC, PTMC and non-PTMC. The BRAF V600E mutation rate of ultrasound-guided fine-needle aspiration cytology was higher compared with FFPE in PTMC (P=0.018). In contrast to previous studies, the results of the present study suggested that being female and having a tumor of diameter ≤1 cm were risk factors for LNM, and that the BRAF wild-type of PTMC may be more aggressive than other types. Notably, the position of the tumor in the bilateral thyroid was also an independent protective factor for LNM. Therefore, ultrasound-guided fine-needle aspiration should be recommended for gene analysis (BRAF V600E) in PTMC. In addition, clinicians should consider an individualized treatment according to gene mutations, sex, age, tumor size and the location of the tumor, in order to achieve an improved therapeutic efficacy.

show abstract

Section: Univariate Analysis Multivariate Analysis ------------------contrasting

confidence: 85%

Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Interestingly, our findings definitely demonstrated that the LNM rate was much higher and was correlated with BRAF V600E wild-type in PTMC, which possibly indicated that BRAF V600E mutation in PTMC was less aggressive which was differ from a previous meta-analysis [22] . A study [31] have reported that most PTMC with BRAF V600E mutation did not display BRAF V600E protein expression.…”

Section: Discussionmentioning

confidence: 97%

Comprehensive evaluation of risk factors for lymph node metastasis with papillary thyroid carcinoma in Southwest China patients

Yan

Wang

Luo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: With the increasing incidences of papillary thyroid cancer(PTC), it is important to risk-stratify patients who may have more aggressive tumor biology. This study aimed to evaluate the risk factors for lymph node metastasis with PTC in Southwest China Patients which may provide a substantial reference for clinical diagnosis and treatment. Methods: 1045 PTCs (313 PTMC and 732 non-PTMC) between August 2016 and August 2019 were examined totally (including one Tibetan). BRAF V600E mutation was tested in all samples. The clinical data (gender, age, tumor location, sample source and pathological features) were retrospectively analyzed. Logistic regression analysis was performed to evaluate independent risk factors for LNM. Results: 181 out of 313 PTMC cases (57.8%), 145 out of 732 non-PTMC cases (19.8%) had BRAF V600E mutation, the Tibetan had a double mutation of BRAF L597Q and V600E in two separate lesions. In PTMC, significant difference in gender and sample source was found (BRAF V600E mutation vs. wild-type). In non-PTMC, significant difference in gender was found (BRAF V600E mutation vs. wild-type). The female (OR=1.952; 95% CI= 1.373-2.774; P= 0.00), age (31-59 years) and diameter of tumor ≤1cm (OR=3.273; 95% CI= 2.417-4.432; P=0.000) were significant independent predictors of LNM in all PTCs. In PTMC, the female (OR= 3.002; 95% CI= 1.654-5.446; P= 0.00) was a significant independent predictor of LNM. The tumor in left and right lobes simultaneously was an independent protective factor of LNM in each group (PTCs: OR=0.287; PTMC: OR=0.170; non-PTMC: OR=0.441, respectively). The BRAF V600E mutation rate of US-FNAC was much higher than FFPE in PTMC (P=0.018). Conclusions: Unlike previous research, our findings suggested that the female patients and diameter of tumor ≤1cm were risk factors for LNM and the BRAF V600E wild-type of PTMC might be more aggressive than others. Interestingly, the position of tumor in bilateral thyroid simultaneously was an independent protective factor for LNM. The US-FNA should be recommended for gene analysis (BRAF V600E) in PTMC. The BRAF L597Q mutation may be an independent aggressive factor in the Chinese Tibetan population. Hence, clinicians should consider an individualized treatment according to gene mutation, gender, age, tumor size and location of tumor in order to achieve a better therapeutic efficacy.

show abstract

“…Thyroid cancer accounts for approximately 90% of all endocrine system malignant tumors and 3.1% of all human malignant tumors [1]. Recently, thyroid cancer has become the fastest-growing solid tumor [2]. Among these, papillary thyroid carcinoma (PTC) is the main pathological type, accounting for approximately 89.9% of cases [3].…”

Section: Introductionmentioning

confidence: 99%

Ultrasonographic Diagnosis of Thyroid Papillary Carcinoma Metastasis

Duan¹,

Fu²,

Zhou³

et al. 2023

View full text Add to dashboard Cite

This study selected the medical record data of patients who underwent ultrasound examination and surgical treatment at Shaw Hospital, affiliated with Zhejiang University Medical College, from January 2018 to June 2020 and screened nine high-risk patients with thyroid papillary carcinoma and eight low-risk patients who met the enrollment criteria. The pathological and ultrasonic imaging data of the thyroid nodules and cervical lymph nodes of the enrolled patients were retrospectively analyzed. Clinicopathological aspects: age, number of lesions, lymph node area, and number of lymph nodes were significant. The younger the age, the higher the risk of cancer metastasis; the more the lymph node metastasis areas, the greater the number of lesions, and the higher the risk of cancer metastasis. An ultrasound image analysis of thyroid nodules showed that the number of microcalcifications and lesions was significantly and positively correlated with the risk of cancer metastasis. Ultrasonic image analysis of cervical lymph nodes showed that the indicators of cystic change, the number of calcifications, number of lymph node fusions, and number of clear lymph node boundaries were significantly and positively correlated with the risk of cancer metastasis. This study is crucial in the clinical diagnosis of thyroid papillary carcinoma metastasis and provides a theoretical basis for surgeons to formulate diagnosis and treatment plans for thyroid carcinoma.

show abstract

An Animal Model Further Uncovers the Role of Mutant Braf during Papillary Thyroid Cancer Development

Cited by 3 publications

References 36 publications

Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma

Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma

Comprehensive evaluation of risk factors for lymph node metastasis with papillary thyroid carcinoma in Southwest China patients

Ultrasonographic Diagnosis of Thyroid Papillary Carcinoma Metastasis

Contact Info

Product

Resources

About